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Abstract
Background—Although recent studies have identified the presence of phenotypic clusters in
asthmatic patients, the clinical significance and temporal stability of these clusters have not been
explored.
Objective—Our aim was to examine the clinical relevance and temporal stability of phenotypic
clusters in children with asthma.
Methods—We applied spectral clustering to clinical data from 1041 children with asthma
participating in the Childhood Asthma Management Program. Posttreatment randomization
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follow-up data collected over 48 months were used to determine the effect of these clusters on
pulmonary function and treatment response to inhaled anti-inflammatory medication.
Results—We found 5 reproducible patient clusters that could be differentiated on the basis of 3
groups of features: atopic burden, degree of airway obstruction, and history of exacerbation.
Cluster grouping predicted long-term asthma control, as measured by the need for oral prednisone
(P < .0001) or additional controller medications (P = .001), as well as longitudinal differences in
pulmonary function (P < .0001). We also found that the 2 clusters with the highest rates of
exacerbation had different responses to inhaled corticosteroids when compared with the other
clusters. One cluster demonstrated a positive response to both budesonide (P = .02) and
nedocromil (P = .01) compared with placebo, whereas the other cluster demonstrated minimal
responses to both budesonide (P = .12) and nedocromil (P = .56) compared with placebo.
Conclusion—Phenotypic clustering can be used to identify longitudinally consistent and
clinically relevant patient subgroups, with implications for targeted therapeutic strategies and
clinical trials design.
Keywords
Childhood asthma; asthma phenotypes; inhaled corticosteroids; cluster analysis; asthma
classification; longitudinal study
Asthma is characterized by chronic airway inflammation, airways hyperresponsiveness, and
reversible airflow limitation.1 The Global Initiative for Asthma guidelines2 and multiple
large-scale clinical trials3–5 have helped to guide current evidence-based treatments. The
current stepwise therapeutic approach is designed to maximize the overall level of asthma
control and medication adherence while minimizing treatment cost and adverse side effects.
However, it has been observed that subsets of asthmatic children not only respond
differently to medications6–8 but also exhibit markedly different disease trajectories, with
some children outgrowing their asthma by early adolescence and others having disease
progression9–12 or decreased lung function in adulthood.13 The lack of distinct histologic
features or reliable quantitative biomarkers suggests that asthma might represent a collection
of diverse disorders with distinct causes and natural histories. Such heterogeneity poses
significant clinical challenges, particularly in regard to long-term prognostication and
treatment decision making.
Numerous classification schemes have been proposed to account for this
heterogeneity.8,14–16 Although tailored treatment strategies are suggested for patients with
distinct forms of disease, most classification schemes have limited utility in guiding
management strategies or reliably predicting long-term morbidity. Recognition of these
limitations has motivated the development of multivariate models that consider many patient
characteristics simultaneously.17–19 More recently, newer data generation procedures that
leverage sophisticated statistical approaches have been applied to large asthma cohorts, with
early success in defining previously unrecognized clusters of asthmatic patients.20–22
However, these studies were limited by their lack of prospective follow-up data, precluding
assessment of the utility of these classification schemes in informing treatment decisions or
disease prognostication.
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It is in this context that we present the results of a phenotype-based cluster analysis of
asthmatic children aged 5 to 12 years who participated in the 48-month Childhood Asthma
Management Program (CAMP) trial3,23 and demonstrate that computational approaches can
define meaningful clusters with both longitudinal consistency and differing responses to
medical therapy.
METHODS
Study population
The CAMP study design and primary outcomes have been described.3,23 Subjects aged 5 to
12 years were eligible if they (1) had a history of mild-to-moderate persistent asthma
defined by the presence of symptoms at least twice weekly, the use of an inhaled
bronchodilator at least twice weekly, or the use of daily medication for asthma; (2) had
greater than 7 days of symptoms or decreased peak expiratory flow rates during the 28-day
run-in period when taking only albuterol as needed; (3) exhibited airway
hyperresponsiveness to methacholine; and (4) had no other clinically significant conditions.
Participants were randomized to receive 200 μg of budesonide twice daily (n = 311;
Pulmicort; AstraZeneca, Westborough, Mass), 8 mg of nedocromil sodium (n = 312; Tilade;
Rhone–Poulenc Rorer, Collegeville, Pa), or matching placebo (n = 418). Subjects were
evaluated every 4 months for 48 months. Asthma exacerbations were treated with short
courses of oral prednisone. The addition of beclomethasone dipropionate (168 μg twice
daily; Vanceril, Schering-Plough, Kenilworth, NJ) was allowed if asthma control was
inadequate. If control remained unsatisfactory, replacement or additional medications were
allowed.
Variable selection
Asthma history interviews were conducted before and spirometry and methacholine
challenge testing were performed after a 28-day screening period off all anti-inflammatory
asthma medications. From an initial list of 48 clinical variables (see Table E1 in this article’s
Online Repository at www.jacionline.org), we selected 18 variables as representative of
each child’s objective risk factors for increased asthma burden as inputs for the clustering
algorithm. We excluded several clinical variables that were included in prior cluster analysis
studies, including asthma symptoms. These symptom variables were purposely excluded
from the model for several reasons, including the following: (1) asthma symptoms were not
evaluated as an outcome in the original CAMP study, (2) descriptions of asthma symptoms
were obtained from daily symptom diaries maintained by study participants and subject to
reporting bias, and (3) there was increased variability in the response rate and number of
missing values for the symptoms described in the diaries.
Also, in contrast to prior cluster analyses, potential asthma risk factors, such as sex,
ethnicity, and environmental exposure, were purposely excluded from cluster model
building. Our rationale for excluding this demographic information was our desire to test the
hypothesis that sex and ethnic factors play a role in the pathogenesis of childhood asthma.
Cluster analysis provided the opportunity to evaluate the segregation of these variables
independent of the model-building process. For this reason, we excluded sex and ethnicity
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for our model and instead included hypothesis testing of these variables after building the
phenotypic clusters.
Cluster analysis
We used spectral clustering to perform cluster analysis.24 In recognition that clustering is
dependent on user-defined inputs, we used an iterative approach over a range of clusters (1
cluster up to a maximum of 8 clusters) to define the optimal number of clusters to form. For
each iteration, cluster centers were generated by means of random sampling of the data
eigenvector matrix. We used the gap statistic to select the optimal number of clusters. The
gap statistic reflects the difference between within-cluster dispersion and that expected
under an appropriate null distribution.25 Further details of the cluster-building methodology
are provided in the Methods section in this article’s Online Repository at
www.jacionline.org.
Statistical analysis of phenotypic clusters
We explored between-cluster differences in baseline clinical, demographic, and
environmental covariates that were not included in the original model by using Kruskal-
Wallis and χ2 tests and used Kaplan-Meier estimates of cumulative probability and Cox
proportional hazards models to evaluate 2 prospective outcomes, including time to first
course of prednisone and time to initiation of alternate antiasthma therapies. We used linear
mixed-effects models to examine between-cluster differences in prospective measures of
lung function and PC20.
RESULTS
Cluster analysis
The baseline characteristics for all 1041 participants are presented in Table E2 in this
article’s Online Repository at www.jacionline.org. As previously reported,23 the
demographic composition of the CAMP cohort is consistent with that of patients with
childhood asthma in North America, including a higher proportion of boys, early age of
onset, and high prevalence of atopic features.
We performed spectral clustering of 18 baseline phenotypic characteristics and optimized
our model selection by calculating a gap statistic for different clustering models. Our results
demonstrated 5 distinct phenotypic clusters.
All but 5 of the variables included in the final model were distributed differentially across
clusters (Table I). Despite their prominence in previously described asthma classification
schemes,20–22 no between-cluster differences were observed in this study for
anthropomorphic measures or circulating leukocyte levels (Table I).
Phenotypic characterization of asthma clusters
The essential features of each cluster can be characterized with respect to 3 groups of
factors: (1) atopic burden (prevalence of atopic dermatitis (AD), allergic rhinitis or skin
reactivity, and total serum IgE and circulating eosinophil levels); (2) lung function and
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airway lability (prebronchodilator FEV1, FEV1/forced vital capacity [FVC] ratio,
bronchodilator response, and methacholine airways hyperresponsiveness [PC20]); and (3)
baseline exacerbation history (prior hospitalization and emergency department [ED] visits;
Box 1). From these groupings, we constructed an Atopy-Obstruction-Exacerbation (AOE)
scoring scheme, assigning low, medium, or high scores for each factor group (Table I). For
clarity of subsequent discussion, although prospective long-term asthma control was not
considered in the clustering procedures (only baseline variables were considered), the cluster
groups are also numbered in ascending rank order of poor long-term asthma control (ie, 1 =
best control and 5 = worst control, as defined by need for oral steroid therapy during the 48
months of follow-up observation, see below).
Box 1
Summary of clinical characteristics of asthma clusters (AOE classification)
Cluster 1: Mild asthma with low atopy, obstruction, and exacerbation rate (LLL)
• Largest subgroup of patients (28.8%)
• No history of AD, lowest prevalence of hay fever or skin prick test reactivity,
lowest IgE levels
• Preserved lung function (highest FEV1/FVC ratio)
• Lowest bronchodilator response, intermediate airway hyperresponsiveness
• No prior hospitalization for asthma and lowest reported prevalence of ED visits
• Lowest risk of exacerbation*
Cluster 2: Atopic asthma with low levels of obstruction and medium rates of
exacerbation (HLL)
• Universally report AD, high prevalence of allergic rhinitis and skin test
reactivity
• Preserved lung function (highest FEV1)
• Intermediate bronchodilator response and airways hyperresponsiveness
• No prior hospitalization, low rates of prior ED visits
• Low-to-intermediate risk of exacerbations*
Cluster 3: Atopic asthma with high levels of obstruction and medium rates of
exacerbation (HHM)
• Rarely report AD (in contrast to HLM cluster) but highest prevalence of allergic
rhinitis and skin test reactivity
• Most reduced lung function (lowest FEV1 and FEV1/FVC ratio)
• High bronchodilator response and most severe airways hyperresponsiveness
• Few prior hospitalizations but intermediate rates of prior ED visits (similar to
HLM cluster)
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• Intermediate risk of exacerbations*
Cluster 4: Moderately atopic asthma with high levels of obstruction and high
exacerbation rates (MHH)
• No history of AD, intermediate prevalence of hay fever (52.9%), lower IgE
levels
• Reduced lung function (low FEV1/FVC ratio, similar to HHH cluster)
• High bronchodilator response and high airways hyperresponsiveness
• Most reports of prior hospitalization
• Intermediate-to-high risk of exacerbation*
Cluster 5: Highly atopic asthma with high levels of obstruction and high
exacerbation rates (HHH)
• Smallest subgroup of patients (9.3%)
• Nearly universal AD, highest prevalence of skin test reactivity, highest IgE
levels, highest eosinophilia, intermediate prevalence of allergic rhinitis
• Reduced lung function (low FEV1/FVC ratio, similar to MHH cluster)
• Highest bronchodilator response and severe airways hyperresponsiveness
• Most reports of prior hospitalization and highest rate of ED visits
• Highest risk of exacerbation*
*Poor long-term asthma exacerbation risk is defined from prospective survival analysis of
time to first course of oral prednisone. This variable was derived by using the defined
cluster groupings and was therefore not considered in spectral cluster analyses used to
define the clusters.
The largest group of patients (cluster 1, 28.8% of cohort) represents the mildest cases with
the fewest prior exacerbations, the lowest prevalence of atopic features, and preserved lung
function (AOE classification LLL). The smallest cluster, cluster 5 (9.3%), consists of the
most severe cases with the highest report of prior exacerbation, a very high atopic burden,
and reduced lung function (AOE group HHH). The 3 remaining clusters reflect subsets with
intermediate levels of severity and more heterogeneous clinical features. Cluster 2 (19.3%)
includes those subjects with high atopic burden but preserved lung function (relative to the
other groups) and intermediate airways hyperresponsiveness. This group has a low baseline
ED visit rate and no reports of prior hospitalization (AOE group HLL). Patients in cluster 3
(20.9%) have high atopy burden, the most compromised lung function, and extreme airways
hyperresponsiveness but have intermediate ED visit rates and only 1 report of prior
hospitalization (AOE group HHM). In contrast, although patients in cluster 4 (21.6%) are
substantially less atopic than those in cluster 2 and have reduced lung function at levels
similar to those in cluster 3, they report higher ED visit rates, and nearly all report prior
hospitalization for asthma (AOE group MHH). It is clear that no single feature is sufficient
to characterize these groups.
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When we developed the phenotypic clusters, we did not include multiple demographic,
environmental, and symptom variables in the development of our model. However, we
explored the presence of between-cluster differences for these variables and found that with
the exception of age, for which statistically significant differences were observed across
cluster groups, demographic variables, including sex and socioeconomic indicators, did not
differ. This finding differed from previously reported cluster analyses, which found
between-cluster differences in demographic variables. Details of these findings are reported
in the Results section in this article’s Online Repository at www.jacionline.org.
Temporal stability of phenotypic clusters
We evaluated the temporal stability of the phenotypic clusters by assessing longitudinal
differences in exacerbation rates and multiple measures of pulmonary function between
different clusters. We assessed the clinical and prognostic relevance of the derived cluster
designations by performing survival analysis of time to asthma exacerbation over 48 months
of follow-up. Because the original CAMP study involved the randomization of medical
therapies, we were able to make an unbiased assessment of between-cluster differences in
response to treatment. Kaplan-Meier analysis confirmed that cluster grouping was predictive
of time to the first course of oral prednisone (log-rank P < .0001; Fig 1, A) and time to
initiation of additional asthma controller therapy (P <.0001; Fig 1, B). Within the first 12
months after randomization, in clusters 4 and 5 a minority of subjects (34% [95% CI, 29%
to 42%] and 36% [95% CI, 25% to 44%], respectively) had not required at least 1 course of
oral steroids compared with 44% (95% CI, 38% to 51%) and 46% (95% CI, 39% to 52%) of
subjects in clusters 3 and 2 and 54% (95% CI, 48% to 60%) of subjects in cluster 1. These
established trends persisted for the remainder of the trial, with greater separation of cluster
groupings over time. At 4 years, the 2 most extreme groups exhibited a 3-fold difference in
their lack of requirement for oral prednisone (32% [95% CI, 27% to 37%] in cluster 1 vs
11% [95% CI, 5% to 18%] in cluster 5, P < .0001). Similar relationships were noted for time
to initiation of additional asthma controller therapies (Fig 1, B).
With 4 years of prospective follow-up as part of the CAMP clinical trial, we were able to
assess the longitudinal consistency in airway hyperresponsiveness and pulmonary function
across the 5 identified clusters using linear mixed-effects models. For methacholine PC20,
prebronchodilator and postbronchodilator FEV1, and prebronchodilator and
postbronchodilator FEV1/FVC ratio, we observed statistically significant (P < .0001)
between-cluster differences across time (Fig 2). Values for methacholine PC20, FEV1, and
FEV1/FVC ratio demonstrated similar temporal patterns, with cluster 3 (HHM) having
relatively lower values than cluster 1 (LLL) across time and minimal overlap in the
trajectories of the clusters with the most extreme values. These temporal differences are
aligned with baseline assessment of airway obstruction (Table I) and differ from baseline
assessments of exacerbation rates, where cluster 5 (HHH) had the highest rate of
exacerbations and cluster 1 (LLL) had the lowest rate.
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Cluster grouping correlates with prospective long-term asthma control and response to
specific inhaled anti-inflammatory controller medications
We next assessed whether treatment response to specific inhaled anti-inflammatory
controller medications differed by cluster group. As originally reported in the primary
outcomes assessment of the CAMP trial,3 use of inhaled budesonide significantly reduced
the number of asthma exacerbations compared with placebo in all phenotypic clusters. A
further finding was that nedocromil did not significantly reduce exacerbation rates or
additional controller therapies compared with placebo. However, in a post hoc evaluation
stratified by cluster grouping, we observed heterogeneity in treatment response rates to both
medications (Fig 3 and Table II; and see Table E3 in this article’s Online Repository at
www.jacionline.org). We found that subjects stratified to the 3 more mild clusters (clusters
1, 2, and 3) demonstrated treatment response patterns similar to those reported in the cohort
as a whole. However, in the 2 most severe clusters (clusters 4 and 5), we found that the
therapeutic efficacy of nedocromil appeared to be more similar to that of budesonide.
Subjects in cluster 4, those with the lowest atopic burden, worst lung function, and high
baseline exacerbation rates, demonstrated a significant reduction in exacerbation rates when
randomized to nedocromil (1.7-fold [95% CI, 1.4-fold to 2.2-fold] reduction compared with
placebo at 12 months and 1.6-fold [95% CI, 1.1-fold to 1.6-fold] reduction at 4 years) that
was similar (log-rank P = .96 for difference) to the reductions observed among those
randomized to budesonide (1.6-fold [95% CI, 1.3-fold to 2.0-fold] reduction compared with
placebo at 12 months and 1.4-fold [95% CI, 1.0-fold to 1.5-fold] reduction at 4 years). For
subjects in cluster 5, those with a high atopic burden, low lung function, and the highest
baseline exacerbations, there was no decrease in exacerbation rates for subjects randomized
to either nedocromil or budesonide (compared with placebo; log-rank P = .56 and .12,
respectively).
Comparisons with previously reported cluster groupings of asthma
To assess the generalizability of our cluster analysis, we compared our results with those of
2 prior cluster analyses of subjects from the Severe Asthma Research Program (SARP)
cohort, one in a pediatric population20 and one in a cohort of pediatric and adult subjects.22
Although both the SARP study and current study used unsupervised multivariate statistical
methods for cluster determination, the variables included in the initial clustering model were
different. The SARP studies included a mixture of both demographic and disease descriptive
variables, whereas the current study included only disease descriptive variables in the initial
model. In addition, the CAMP cohort was the only one that controlled for the use of inhaled
corticosteroids (Table III), allowing for a formal test of differential response to therapy
between clusters.
The asthma subgroups defined by both the SARP childhood study and the current CAMP
study were similar with respect to the degree of atopy, airway obstruction, and exacerbation
rates present within each of the subgroups (Table III). However, several differences exist
between the 2 studies, including the absence in the SARP cohorts of a cluster with a low
degree of atopy and a high degree of both airway obstruction and exacerbation rates (cluster
4 in the CAMP study).
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Furthermore, differences in the degree of atopy between clusters are more pronounced in the
CAMP cohort than the SARP cohorts. For example, for the CAMP clusters, there are
multiple clusters in which almost 100% of the subjects have a history of AD (cluster 2,
100%; cluster 5, 97.9%) and multiple clusters in which almost none of the subjects have a
history of AD (cluster 1, 0%; cluster 4, 0%; cluster 3, 0.1%). For the SARP clusters, the
difference in the history of AD is comparatively less, with within-cluster incidence ranging
from 47% to 72%. In addition, the degree of spread for the serum IgE variable is different
between the SARP and CAMP clusters, with a greater degree of spread present among the
CAMP clusters when compared with the SARP clusters (234–645 vs 105–405 kU/L,
respectively).
There are also many similarities between the CAMP clusters and the clusters generated from
a cluster analysis of adults from the SARP study. Similar to the CAMP and childhood SARP
clusters, the mixed adult and pediatric SARP clusters are comparable with respect to the
degree of airway obstruction and exacerbation rates present within the clusters (Table III).
However, the SARP clusters with a higher proportion of adults differ from both the CAMP
and childhood SARP clusters in that the overall degree of atopy present, as determined by
serum IgE level, is less for the adult than the childhood populations. The lowest IgE level
for the childhood clusters (105 kU/L for childhood SARP cluster 1) is almost as high as the
highest IgE level for the adult clusters (141 kU/L for adult SARP cluster 1). Additionally,
the degree of airway obstruction present in the adult population is much greater in the adult
population, with FEV1/FVC ratios for each cluster ranging from 0.57 to 0.78 in the adult
population versus 0.78 to 0.82 in the CAMP and 0.72 to 0.82 in the childhood SARP
populations.
DISCUSSION
The clinical heterogeneity of asthma has motivated the use of machine-learning algorithms
for the classification of patients using data-driven unbiased criteria. Although earlier
work20–22 established the feasibility of this approach, many important questions remain
unaddressed, including issues of reproducibility, generalizability, and clinical relevance.
Without longitudinal follow-up, which was unavailable in prior reports, it is unclear whether
the defined clusters have clinical utility. It is in this context that the results of our phenotypic
clustering efforts and longitudinal analysis can be summarized.
First, we demonstrate the longitudinal consistency of our phenotypic clusters. When we
developed the clusters, we limited ourselves to the clinical data obtained during baseline
assessment of CAMP participants. Next, we evaluated for changes in cluster membership
over the 48-month study period and found remarkable consistency in phenotypic
distributions over time, particularly with regard to airway hyperresponsiveness, obstruction,
and exacerbation rates. These findings echo those of a recent longitudinal cluster analysis
that found membership in phenotypic clusters to be extremely stable over time.26 An
additional finding of our study was that different inhaled anti-inflammatory medications
appeared to have no statistically significant effect on cluster membership over time,
suggesting that although these medications might affect day-to-day symptoms, they have
minimal effect on the natural history of childhood asthma.
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Second, we demonstrate the therapeutic benefit of our phenotypic clusters. We found
important between-cluster differences in response to inhaled asthma therapies, with one
cluster (cluster 4) showing decreased rates of exacerbations with both budesonide and
nedocromil therapy and another cluster (cluster 5) showing poor response with both
budesonide and nedocromil therapy. Our data suggest that although inhaled corticosteroids,
such as budesonide, should serve as the primary treatment choice for asthma control in
children with mild-to-moderate asthma, there are several subgroups of patients, including
those with the poorest level of baseline asthma control, who appear to respond to nedocromil
at levels similar to budesonide. Given safety concerns, particularly in children, regarding the
long-term exposure to inhaled glucocorticoid therapy, identification of phenotypic clusters
that could benefit similarly from nonsteroidal therapies would be of great value. Although
the retrospective nature of the current study and the small size of several of the clusters
limits our ability to draw firm clinical conclusions about the current results, our findings
serve as the foundation for future prospective clinical trials investigating personalized
responses to inhaled anti-inflammatory medications.
Finally, despite notable differences in the compositions of the patient populations, the
computational algorithms used, and the variables considered in generating the clusters, our
results show remarkable consistency with those obtained in the pediatric and adult SARP
populations, both with respect to the number of phenotypic clusters identified (5–6 clusters
in CAMP and SARP cohorts) and the characteristics of individual clusters.20–22 The
similarity of our phenotypic clusters to those of other cohorts provides further evidence for
the potential generalizability of clustering as a method of phenotyping asthmatic patients.
Observed differences in the degree of atopy and airway obstruction present in the pediatric
compared with adult clusters lend further support to the hypothesis of etiologic differences
between childhood and adult asthma.
Our study had several limitations. First, we evaluated only children, and reports have shown
that pediatric and adult asthma might represent 2 different disease states with different
pathogenic mechanisms and natural histories.27 For this reason, the clinical implications of
this cluster analysis might not be widely applicable to an adult asthmatic population.
Second, our study did not include patients with severe childhood asthma. Because our
original population was ascertained for the purposes of a clinical trial, it included children
with mild-to-moderate persistent asthma and specifically excluded those with more severe
asthma. Thus there is a possibility that there is a severe childhood asthmatic phenotypic that
was missed with our analysis, although the strong similarities in observed clusters with the
childhood SARP study (which included a broader spectrum of disease severity) provide
reassurance that the results of our cluster analysis are more widely applicable.
Third, the conclusions that we can draw from the clinical outcomes of our clusters are
limited because of their small sample size and modest differences. For example, the children
in cluster 5 had a limited response to inhaled budesonide and nedocromil compared with
placebo, suggesting that the children in this cluster might have some resistance to
corticosteroid therapy. However, because there were only 96 children in this cluster, we
were underpowered to draw more clinically meaningful conclusions from this particular
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analysis. It will be necessary to validate some of these preliminary findings in future
prospective studies to determine whether the children in this cluster are truly steroid
resistant.
In conclusion, our results support the use of computationally inferred phenotypic
classifications of asthma as having clinical utility. These models define subsets of patients
with unique clinical attributes, discrete clinical trajectories, and variable responsiveness to
antiasthma controller medications. Recognition of these clusters and their clinical relevance
should motivate novel strategies in both the research and clinical settings. More refined
phenotypic classification might better inform treatment decisions: as suggested by the results
of our treatment responsiveness analysis, cluster assignment identifies 2 subsets of patients
who respond similarly to both budesonide and nedocromil, providing clinicians with viable
treatment options for patients at risk for corticosteroid-related complications. The observed
between-cluster differences in environmental and genetic factors suggest that important
etiologic differences underlie the configuration of different asthma subgroups. Future studies
that consider more homogenous subsets of patients should improve research precision in
characterizing the genetic and environmental causes. Thus in addition to helping inform
clinical management, these more refined phenotypic classification schemes should help
accelerate research efforts in defining the molecular and environmental underpinnings of
this complex airways disease.
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Clinical implications
Childhood asthma is heterogeneous. The current cluster analysis suggests that
heterogeneous phenotypic clusters of asthmatic children remain stable over time, even
after treatment with different medical therapies.
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FIG 1.
Kaplan-Meier plots by cluster of the cumulative probability of a first course of prednisone
(A) or initiation of additional asthma controller therapies (beclomethasone or other; B)
during the 4-year follow-up period of the CAMP trial.
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FIG 2.
Mean pulmonary function measurements for each phenotypic cluster evaluated over 48
months of follow-up. P values for between-cluster differences among all longitudinal
measures were less than .0001, as calculated by using linear mixed-effects models.
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FIG 3.
Kaplan-Meier estimate by treatment group of the cumulative probability of prednisone use
during 4 years of follow-up stratified by phenotypic cluster. B, Budesonide; N, Nedocromil.
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TABLE III
Comparison of study design and results from independent asthma phenotype clustering analyses
CAMP (current study) SARP childhood study SARP adult study
Sample size 1041 161 726
Age distribution (y) 5–13 6–17 12–80
Percentage non-Hispanic white 68 39 64
Inclusion criteria Dx, AHR, BDR
No active symptoms
Dx, AHR, BDR
No active symptoms
Dx, nonsmokers
ICS at time of evaluation No Yes × 6 mo Yes
Spectrum of severity at enrollment Mild to moderate Mild to severe Mild to severe
Variables included in model 18 12 34
No. of clusters 5 4 5
AOE cluster subtypes
 1. LLL Cluster 1 (28.8%) Cluster 1 (29.8%) Cluster 1 (15.2%)
  Descriptor Mild asthma with a low atopic
burden
Late onset, normal lung function Young female subjects with
atopic asthma and normal
lung function
  Age of asthma onset (y) 3.52 6.08
  Total serum IgE (kU/L) 234 105 141
  AD 0% 50%
  Pre-BD FEV1/FVC ratio 0.82 ± 0.8 0.82 ± 0.11 0.78 ± 0.1
  Exacerbation rate (rank) Lowest Lowest Lowest
 2. HLL Cluster 2 (19.4%) Cluster 2 (32.3%) Cluster 2 (44.2%)
  Descriptor Atopic with preserved lung
function
Early onset, atopic, normal lung
function
Older female subjects with
atopic asthma and normal
lung function
  Age of asthma onset (y) 3.09 2.5
  Total serum IgE (kU/L) 524 405 125
  AD 100% 56%
  Pre-BD FEV1/FVC ratio 0.81 ± 0.8 0.79 ± 0.09 0.74 ± 0.1
  Exacerbation rate (rank) Second lowest Second lowest Second lowest
 3. HHM Cluster 3 (20.9%) Cluster 3 (19.9%) Cluster 4 (16.5%)
  Descriptor High obstruction, severe AHR Early onset, atopic, mild airflow
limitation
Childhood-onset atopic
asthma, severe obstruction,
high BDR
  Age of asthma onset (y) 3.66 1.2
  Total serum IgE (kU/L) 616 216 132
  AD 0.1% 47%
  Pre-BD FEV1/FVC ratio 0.78 ± 0.8 0.72 ± 0.10 0.64 ± 0.1
  Exacerbation rate (rank) Third lowest Third lowest Third lowest
 4. MHH Cluster 4 (21.6%) Not represented Cluster 5 (16.0%)
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CAMP (current study) SARP childhood study SARP adult study
  Descriptor Low atopy, high obstruction, high
exacerbation
Childhood-onset atopic
asthma, severe obstruction,
low BDR
  Age of asthma onset (y) 2.21
  Total serum IgE (kU/L) 436 98
  AD 0%
  Pre-BD FEV1/FVC ratio 0.78 ± 0.08 0.57 ± 0.1
  Exacerbation rate (rank) Second highest Second highest
 5. HHH Cluster 5 (9.2%) Cluster 4 (18.0%) Cluster 3 (8.13%)
  Descriptor Exacerbation Early onset, atopic, advanced
airflow limitation
Older women, high BMI, low
atopy, low BDR
  Age of asthma onset (y) 2.68 1.6
  Total serum IgE (kU/L) 645 361 54
  AD 97.9% 72%
  Pre-BD FEV1/FVC ratio 0.79 ± 0.09 0.73 ± 0.10 0.74 ± 0.1
  Exacerbation rate (rank) Highest Highest Highest
AHR, Airway hyperresponsiveness; BD, bronchodilator; BDR, bronchodilator response; ICS, inhaled corticosteroid; Dx, diagnosis.
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